Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
Aldeyra Therapeutics: Key Inflection Point Ahead
04:04am, Thursday, 26'th Dec 2024
Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Drug giant AbbVie has a significant option agreement on Aldeyra's primary pipeline asse
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
11:05am, Monday, 09'th Dec 2024
Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately.
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
07:00am, Monday, 02'nd Dec 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
11:00am, Tuesday, 19'th Nov 2024
The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
05:31am, Thursday, 14'th Nov 2024
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Al
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
07:00am, Thursday, 31'st Oct 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
07:00am, Thursday, 03'rd Oct 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
07:00am, Thursday, 20'th Jun 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
07:00am, Thursday, 13'th Jun 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra Therapeutics to Host Investor Roundtable Q&A
07:00am, Wednesday, 12'th Jun 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission
01:25pm, Monday, 10'th Jun 2024
Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical an
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
07:00am, Wednesday, 29'th May 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
10:46am, Tuesday, 14'th May 2024
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) have performed compared to their sector so far this year.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024
08:52am, Friday, 03'rd May 2024
Aldeyra Therapeutics (NASDAQ: ALDX ) just reported results for the first quarter of 2024. Aldeyra Therapeutics reported earnings per share of -14 cents.
